Immatics N.V. (IMTX)
D
Pipeline Grade
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06743126 | SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cuta... | PHASE3 | Recruiting | 360 |
| NCT03686124 | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors | PHASE2 | Recruiting | 375 |
| NCT05958121 | IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors | PHASE2 | Recruiting | 400 |
| NCT05359445 | IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor | PHASE1 | Active Not Recruiting | 95 |
| NCT06946225 | ACTengine® IMA203 Combined With mRNA-4203 | PHASE1 | Recruiting | 15 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.